Project IMP-ACT
De-risking IMP manufacturing, packaging, and supply for academics. health services,
investigators and university spin-offs running clinical trials under the TGA CTN scheme
Take the anonymous survey today and help shape a new IMP risk assessment tool, a practical resource to help sponsors and institutions.
De-risking IMP manufacturing, packaging, and supply for academics. health services,
investigators and university spin-offs running clinical trials under the TGA CTN scheme
Project IMP-ACT is a national initiative focused on academics, health services, university spin-offs, start-ups, and investigators conducting clinical trials in Australia. Its primary objective is to de-risk the manufacture, preparation, packaging, labelling, and supply of Investigational Medicinal Products (IMPs) for Australian clinical trials conducted under the CTN scheme.
Transitioning a therapeutic discovery from the bench into clinical trials is a major translational milestone. However, operational gaps in Chemistry, Manufacturing, and Controls (CMC), formulation instability, or improper IMP labelling and handling pose substantial risks across participant safety, scientific data integrity, and patent enforceability.
Have your say: Survey closes 24 November · EOI: Executive Roundtable 01 December · Register · Webinar 08 December
📢 We want to hear from you if you are involved in custom-made, compounded or modified IMPs (including over-encapsulation, repackaging or rebottling, changing primary packaging or relabelling for blinded trial supplies)?
We’re seeking input from CTU managers, trial coordinators, research office and technology transfer leads, HREC and RGO teams, investigators and spin-off founders involved in IMP handling and clinical trial compliance.
Ensuring every dose administered meets strict quality, purity, and formulation stability standards
Protecting the scientific accuracy and reproducibility of your trial results against batch degradation
Safeguarding your core IP so your candidate withstands venture capital scrutiny and pharma licensing due diligence
The Australian Clinical Trial Notification (CTN) scheme provides an efficient pathway to start clinical trials, but the TGA does not evaluate product quality data before a trial begins. Responsibility for IMP quality and regulatory compliance rests with the trial sponsor, with institutions and HRECs playing important oversight roles. Seemingly simple activities (over-encapsulation, rebottling, changing primary packaging or blinded relabelling) can create significant obligations that are often underestimated.
Project IMP-ACT comprises five key components:
📊 National Benchmark Survey – Identify current practices, challenges and capability gaps in IMP governance and clinical trial supply.
🤝 Executive Roundtable – Bring together key stakeholders to discuss findings, share perspectives and explore practical solutions.
📄 Industry White Paper – Consolidate insights and develop recommendations to strengthen IMP supply practices in Australia.
🎓 Free Educational Webinar – Share findings, practical insights and recommendations with the wider clinical research community.
🧭 IMP-ACT Risk Assessment Tool: A practical resource, informed by the survey and roundtable, to help sponsors and institutions ask the right questions, assess packaging and stability risks, and know when to seek specialist advice. Preview at the webinar on 8 December.
The survey provides the evidence base, the roundtable supports stakeholder discussion, the white paper captures the findings and recommendations, and the webinar shares these outcomes and previews the Risk Assessment Tool..